Ialt 670 patienter, af hvem 498 var imatinib- resistente, blev randomiseret til dasatinib 100 mg 1 gang dagligt, 140 mg 1 gang dagligt, 50 mg 2 gange dagligt eller 70 mg 2 gange dagligt.
A total of 670 patients, of whom 498 were imatinib-resistant, were randomised to the dasatinib 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily group.